推进先天性心脏病相关慢性心衰的规范化管理:2024年美国心脏协会声明解读  

Advancing the standardized management of congenital heart disease-related chronic heart failure:an interpr-etation of the 2024 AHA scientific statement

作　　者：葛永瑾 张晨美[1] 何玮梅 单佳妮[1] GE Yong-jin;ZHANG Chen-mei;HE Wei-mei(Children's Hospital,Zhejiang University School of Medicine,National Clinical Research Center for Child Health,Hangzhou 310052,China)

机构地区：[1]浙江大学医学院附属儿童医院国家儿童健康与疾病临床医学研究中心,浙江杭州310052

出　　处：《中国实用儿科杂志》2025年第3期194-201,共8页Chinese Journal of Practical Pediatrics

基　　金：国家重点研发计划(2021YFC2701800、2021YFC2701801)。

摘　　要：先天性心脏病(congenital heart disease,CHD)是儿童和青少年慢性心衰的主要病因之一。由于解剖和生理特征的复杂性,其诊疗策略需区别于成人心衰的管理。2024年,美国心脏协会(American Heart Association,AHA)发布科学声明,重点分析了CHD相关慢性心衰的流行病学、病理生理机制、临床分期、诊疗方案。本解读旨在为国内临床医师提供最新循证医学证据,以指导CHD相关慢性心衰的临床管理。Congenital heart disease(CHD)is one of the leading causes of chronic heart failure in children and adolescents.Due to the complexity of anatomical and physiological characteristics,the management strategies for CHD-related heart failure differ from those for adult heart failure.In 2024,the American Heart Association released a scientific statement that provides a comprehensive analysis of the epidemiology,pathophysiology,clinical staging,and management strategies for CHD-related chronic heart failure.This interpretation aims to provide the latest evidence-based medical insights for domestic clinicians to guide the clinical management of CHD-related chronic heart failure.

关 键 词：心力衰竭 先天性心脏病 流行病学 肺动脉高压 射血分数 高血压 心律失常 心室辅助装置 体外膜氧合 心脏移植 指南 共识 

分 类 号：R72[医药卫生—儿科]